Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Category Archives: Yaz, Yasmin & Ocella

Subscribe to Yaz, Yasmin & Ocella RSS Feed

The Nurse Practitioner Warns of Increased Risk of Blood Clot with Drospirenone Use

Posted in Yaz, Yasmin & Ocella

In the “Medication Update” section of a 2011 edition of the medical journal The Nurse Practitioner, a warning regarding the use of drospirenone-containing oral contraceptives is made.  Oral contraceptives containing drospirenone are YAZ®, Beyaz®, Safyal®, and Yazmin®. The warning reads as follows: “The FDA notified healthcare providers and patients that two newly published studies evaluating… Continue Reading

Drospirenone-Containing Contraceptives Implicated as Causal Factor in Heart Attack of Young Woman

Posted in Yaz, Yasmin & Ocella

A 2010 report by the medical journal Reactions describes the case of a 20-year-old woman, otherwise in good health, who suffered a heart attack while taking an oral contraceptive containing the chemical drospirenone, found in contraceptives such as YAZ®. The case of this woman, holding no risk factors for blood clot or heart attack other… Continue Reading

2009 – Study Names Chemical in YAZ® More Dangerous than Other Hormonal Contraceptives

Posted in Yaz, Yasmin & Ocella

An article published in 2009 in the British Medical Journal by Dr. A. van Hylckama Vlieg (et al.) analyzes the risk of developing a blood clot for women using hormonal contraceptives (versus non-users) and evaluates the relative risk for developing a blood clot between different types of hormonal contraceptives used today, naming the active chemical… Continue Reading

American Journal of Nursing Shows Oral Contraceptives Containing Drospirenone are More Dangerous than Others

Posted in Yaz, Yasmin & Ocella

The “Drug Watch” section of the September, 2012 edition of the American Journal of Nursing includes some startling information about hormonal contraceptive drugs containing the chemical drospirenone, such as YAZ,® Beyaz®, Safyral®, and Yasmin®. Reviewing several studies comparing the relative risks of developing a blood clot for women using drospirenone-containing hormonal contraceptives versus women using… Continue Reading

Study Evaluates Relative Risks of Hormonal Contraceptives, Names Yaz® as Particularly Dangerous

Posted in Yaz, Yasmin & Ocella

A study published in May, 2009 by the British Medical Journal notes that women using hormonal contraceptives containing drospirenone, such as Yaz®, are about 64% more likely to develop blood clots than the average woman using hormonal contraceptives.[1]  Blood clots pose a very serious risk to health, as they may cause heart attack or stroke…. Continue Reading

Case Report Names Drospirenone-Containing Hormonal Contraceptive as “Only Associated Risk Factor” in Development of Blood Clot

Posted in Yaz, Yasmin & Ocella

A report published in 2006 in the medical journal Clinical and Applied Thombosis/Hemostasis reviews the case of a woman, aged 36 years, who came under the care of Dr. Y. Mira, presenting deep venous thromboses (blood clots) in the “left jugular and subclavian” veins.[1]  Blood clots are a very serious occurrence, possibly leading to heart… Continue Reading

Study Shows YAZ Places Users at Higher Risk of Hyperkalemia

Posted in Yaz, Yasmin & Ocella

A recent study published in the journal BioMedCentral Pharmacology aimed to evaluate potential health risks posed to users of hormonal contraceptives containing drospirenone, such as YAZ®. In this report, titled “The association between drospirenone and hyperkalemia: a comparative-safety study” a team of researchers led by Dr. ST Bird studied 1,148,183 women, and found that users of drospirenone-containing… Continue Reading

Yaz Lawsuit Filed In Illinois Discussed History of Yaz and Yasmin

Posted in Yaz, Yasmin & Ocella

The following Yaz lawsuit was filed in August of 2008 in the U.S. District Court for the Southern District of Illinois: 13. Yaz and Yasmin are birth control pills manufactured and marketed by Defendants. They are combination oral contraceptives, or “COCs,” meaning that they contain an estrogen component and a progestin component. Together, these steroidal components… Continue Reading